News for Erasca, Inc. (ERAS)

On December 31, 2024, SILVERARC CAPITAL MANAGEMENT, LLC (Trades, Portfolio) made a significant move by acquiring an additional 136,463 shares of Elutia Inc, a c

**media[528995]**

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial position.

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. ( ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing,

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Stellantis N.V. STLA fell sharply in today's pre-mark...

The Global Precision Oncology Market Size was Valued at USD 98.5 Billion in 2023 and the Worldwide Precision Oncology Market Size is Expected to Reach USD...

Loading... Loading... The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or...

Biotech ripe for ‘cascade of dealmaking’ - Here are the top companies to watch

Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday.

On Wednesday, 311 stocks hit new 52-week lows.

IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on...

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Read Research Analysts’ Upgrades for May 30th (AUDC, BGCP, CGEN, DAC, EBKDY, ELS, ENFN, ERAS, ESSA, EVGO) at ETF Daily News